Table 3.

Multivariable analysis of predictors of severity of prevalent chemotherapy-induced peripheral neuropathy in the Detroit Research on Cancer Survivors (ROCS) cohort

	aOR*	Lower CI	Upper CI
Demographics Age at Diagnosis
< 50	2.11	1.30	3.43
51–64	1.84	1.21	2.81
65 +	Ref
Trend	0.70	0.55	0.89
Marital status
Married or equivalent	1.18	0.77	1.80
Widowed	0.93	0.49	1.78
Divorced or separated	1.34	0.86	2.07
Never married	Ref
Educational attainment	0.84	0.73	0.97
Cancer characteristics
Cancer Site
Breast	0.52	0.19	1.44
Colorectal	0.57	0.20	1.61
Lung	0.35	0.12	1.03
Prostate	ref
SEER summary stage
Local	ref
Regional	1.29	0.90	1.85
Distant	1.43	0.87	2.34
Trend	1.21	0.95	1.54
Medical history
Body Mass Index (BMI) at Enrollment (per category)	1.06	0.85	1.32
Comorbidity Count
None	ref
1	1.53	0.77	3.05
2	1.46	0.73	2.94
3	1.80	0.86	3.76
4 or more	1.98	0.97	4.07
Trend	1.14	0.99	1.31
Diabetes mellitus
Yes	0.83	0.54	1.29
No	ref
Thyroid problem
Yes	1.01	0.61	1.70
No	ref
Arthritis
Yes	1.55	1.06	2.26
No	ref
Smoker (≥ 100 cigs lifetime)
Yes	1.07	0.76	1.50
No	ref
Alcohol use (in the past 4 weeks)
Yes	1.00	0.72	1.38
No	ref

^*Multivariable adjustment for age at diagnosis, education, comorbidity count, arthritis

Severity of chemotherapy-induced peripheral neuropathy (CIPN) was coded as mild, moderate or severe symptoms. Comparisons were for symptoms ranked as high or severe vs. low (mild or moderate). The results in this table are based on 704 individuals with prevalent CIPN of which 224 had mild severity and 480 had moderate or severe CIPN Bold values denote statistical significance at p<0.05